Agilent resolution ctdx first receives fda approval as a liquid biopsy companion diagnostic test for advanced non-small cell lung cancer

Santa clara, calif.--( business wire )--agilent technologies inc. (nyse: a) announced today that the u.s. food and drug administration (fda) has approved agilent resolution ctdx first as a companion diagnostic (cdx) to identify advanced non-small cell lung cancer (nsclc) patients with kras g12c mutations who may benefit from treatment with krazati tm (adagrasib).
A Ratings Summary
A Quant Ranking